thecardiologyadvisor.com4h
Extended Nirmatrelvir/Ritonavir Beneficial for Some With Long COVID
Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist.
Emerging Cancer Breakthroughs to Watch in 2025: The Next Wave of Life-Saving Innovations
From groundbreaking immunotherapies to advanced targeted treatments, oncology is set to make historic strides in the year ahead.
BioSpace4h
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.
Antibody Drug Conjugates Market Outlook 2025-2035, with Forecasts for Payload Type, Linker Type, Target Antigen and Applications
The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...
Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025
Read here for more on the potential of RCUS's combination therapies for various cancers, with promising Phase 3 trials and ...